IP Library Granted Patent US 6,852,106
Granted Patent B2
US 6,852,106 · App. 10/013,946 · Granted Feb 8, 2005

Implantable refillable and ported controlled release drug delivery device

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,852,106
App. No.
10/013,946
Granted
Feb 8, 2005
Kind
B2
Abstract

An implantable, refillable, rate controlled drug delivery device is disclosed that includes a base structure having at least a first opening and a second opening, the base structure defining a chamber, a septum covering the first opening and configured to substantially prevent leakage from the first opening to an exterior of the device, a drug delivery tube comprising a first and second distal end, wherein the first distal end of the tube communicates with the chamber through the second opening, and at least one rate-limiting permeable membrane disposed across a passage between the base structure and the second distal end of the drug delivery tube, which membrane passively regulates drug delivery. The drug delivery device is used to provide controlled drug delivery to an internal portion of the body and is advantageously leak-proof and does not rely on a pressure differential to drive the drug from the device.

Claims (43)

1. An implantable, refillable, rate controlled drug delivery device, comprising:

a base structure having at least a first opening and a second opening, the base structure defining a chamber;

a septum covering the first opening and configured to substantially prevent leakage from the first opening to an exterior of the device;

a drug delivery tube comprising a proximal end and a distal end, wherein the proximal end of the tube communicates with the chamber through the second opening, and

at least one rate-limiting permeable membrane disposed at least partially within said chamber and across a passage between the base structure and said drug delivery tube proximal end, which membrane passively regulates drug delivery.

2. The implantable, refillable, rate controlled drug delivery device according to claim 1 , wherein the device comprises two rate-limiting permeable membranes.

3. The implantable, refillable, rate controlled drug delivery device according to claim 1 wherein said at least one rate-limiting permeable membrane is disposed entirely within the chamber.

4. The implantable, refillable, rate controlled drug delivery device according to claim 3 , wherein the septum comprises one of a polyvinyl alcohol, ethylene vinyl acetate, silicone, nylon, polypropylene, polycarbonate, cellulose, cellulose acetate, cellulose esters, polymer composites, Poly(2,6-Dimethylphenylene oxide), or polyether sulfone.

5. The implantable, refillable, rate controlled drug delivery device according to claim 1 , wherein the chamber contains a drug to be delivered at a controlled rate to a target area of the body.

6. The implantable, refillable, rate controlled drug delivery device according to claim 5 , wherein the target area of the body is the brain and the device is configured to deliver the drug thereto.

7. A method of controlling drug delivery to an internal portion of a body comprising administration of a drug to an internal portion of the body through a device according to claim 1 to control delivery of the drug.

8. The implantable, refillable, rate controlled drug delivery device according to claim 1 , wherein the septum comprises one of a polyvinyl alcohol, ethylene vinyl acetate, silicone, nylon, polypropylene, polycarbonate, cellulose, cellulose acetate, cellulose esters, polymer composites, Poly(2,6-Dimethylphenylene oxide), or polyether sulfone.

9. The implantable, refillable, rate controlled drug delivery device according to claim 1 , wherein the septum comprises at least one of a silicone elastomer, polyurethane elastomer, and polysulfide elastomer.

10. The implantable, refillable, rate controlled drug delivery device comprising:

a base structure having at least a first opening and a second opening, the base structure defining a chamber;

a septum covering the first opening and configured to substantially prevent leakage from the first opening to an exterior of the device;

a drug delivery tube comprising a proximal end and a distal end, wherein the proximal end of the tube communicates with the chamber through the second opening;

a rate-limiting permeable membrane disposed at least partially within said chamber and across a passage between the base structure and said drug delivery tube proximal end, which membrane passively regulates drug delivery;

a filter housing provided within the chamber adjacent the second opening; and

a filter element provided between the rate-limiting permeable membrane and the filter housing.

11. The implantable, refillable, rate controlled drug delivery device according to claim 10 , wherein an upper portion of the filter housing comprises a needle stop.

12. The implantable, refillable, rate controlled drug delivery device according to claim 11 , wherein the upper portion of the filter housing comprising a needle stop is disposed over the second opening.

13. The implantable, refillable, rate controlled drug delivery device according to claim 12 , wherein the upper portion of the filter housing comprising a needle stop comprises a plurality of perforations.

14. The implantable, refillable, rate controlled drug delivery device according to claim 10 , further comprising:

a retaining ring for compressively securing the septum in place.

15. The implantable, refillable, rate controlled drug delivery device according to claim 14 , wherein the retaining ring and the base structure comprise a biologically compatible metal.

16. The implantable, refillable, rate controlled drug delivery device according to claim 15 , wherein the biologically compatible metal comprises one of titanium or stainless steel.

17. The implantable, refillable, rate controlled drug delivery device according to claim 14 , wherein the retaining ring and the base structure comprise a substantially rigid non-metallic biologically compatible material.

18. The implantable, refillable, rate controlled drug delivery device according to claim 17 , wherein the biologically compatible material comprises one of a Polysulfone, an ultra-high molecular weight polyethylene, organometallic composites, phenolics, unsaturated polyesters, epoxy resins, polycarbonate, polyacetal, nylon, polyimide, and a pyrolytic carbon.

19. A method of controlling the delivery of a drug to an internal portion of a body comprising:

administering a drug to an internal portion of the body through a device according to claim 14 to control the delivery of the drug.

20. An implantable, refillable, rate controlled drug delivery device comprising:

a base structure having at least a first opening and a second opening, the base structure defining a chamber;

a septum covering the first opening and configured to substantially prevent leakage from the first opening to an exterior of the device;

a drug delivery tube comprising a proximal end and a distal end, wherein the proximal end of the tube communicates with the chamber through the second opening;

at least one rate-limiting permeable membrane disposed across a passage between the base structure and the distal end of the drug delivery tube, which membrane passively regulates drug delivery;

a filter housing provided within the chamber adjacent the second opening;

a filter element provided between the rate-limiting permeable membranes and the filter housing, and

a depressed region at least partially circumscribing the second opening,

wherein an upper portion of the filter housing comprises a needle stop,

wherein the upper portion of the filter housing comprising a needle stop is disposed over the second opening,

wherein the upper portion of the filter housing comprising a needle stop comprises a plurality of perforations, and

wherein the rate-limiting permeable membrane is positioned at least partially within the depressed region.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2022
From: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
To: EYEPOINT PHARMACEUTICALS, INC.; EYEPOINT PHARMACEUTICALS US, INC.; ICON BIOSCIENCE, INC.
Reel/Frame 059365/0112 →
SECURITY INTEREST Recorded Feb 13, 2019
From: EYEPOINT PHARMACEUTICALS, INC.; EYEPOINT PHARMACEUTICALS US, INC.; ICON BIOSCIENCE, INC.
To: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 048329/0045 →
RELEASE OF SECURITY INTEREST Recorded Feb 13, 2019
From: SWK FUNDING LLC, AS AGENT
To: PSIVIDA CORP.; PSIVIDA US, INC.; ICON BIOSCIENCE, INC.
Reel/Frame 048329/0136 →
SECURITY INTEREST Recorded Apr 5, 2018
From: PSIVIDA CORP.
To: SWK FUNDING LLC, AS AGENT
Reel/Frame 045848/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2002
From: WATSON, DAVID A.; SHIMIZU, ROBERT W.; LAPORTE, RICHARD
To: CONTROL DELIVERY SYSTEMS, INC.
Reel/Frame 012977/0855 →